Abstract
Background and aimsWe aimed to assess the effects of cholesteryl ester transfer protein inhibitor anacetrapib added to statin ± other lipid-modifying therapies (LMT) in Japanese patients with dyslipidemia who were not at their LDL-C goal. MethodsPatients on a stable dose of statin ± other LMT with LDL-C ≥100 mg/dL to <145 mg/dL, ≥120 mg/dL to <165 mg/dL, ≥140 mg/dL or ≥160 mg/dL for patients with a history of coronary heart disease (CHD), high-, moderate- and low-risk patients respectively, were randomized 2:1, stratified by background therapy, to double-blind anacetrapib 100 mg (n = 204) or placebo (n = 103) for 24 weeks, followed by a 28-week open-label extension phase (anacetrapib 100 mg) and a 12-week off-drug safety follow-up phase. The primary endpoint was percent change from baseline in LDL-C (beta-quantification method), as well as the safety profile of anacetrapib at Week 24; HDL-C was a key secondary endpoint. ResultsAnacetrapib 100 mg further reduced LDL-C (38.0%), non-HDL-C (35.1%), ApoB (28.7%), and Lp(a) (48.3%) and increased HDL-C (148.9%) and ApoAI (50.7%) versus placebo (p < 0.001 for all). There were no meaningful differences between the groups in the proportion of patients with liver enzymes elevations (2.0% vs. 0%), creatine kinase elevations overall (0.5% vs. 0%) or with muscle symptoms (0.5% vs. 0%), blood pressure, electrolytes or adjudicated cardiovascular events (0.5% vs. 0%). In the open–label period, sustained effects on lipid parameters were observed with anacetrapib and the treatment was generally well tolerated. ConclusionsLong-term treatment with anacetrapib 100 mg substantially reduced LDL-C, increased HDL-C and was well tolerated in Japanese patients with dyslipidemia (ClinicalTrials.gov number NCT01760460).
Highlights
The plasma protein cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl esters and triglycerides (TG) between high density lipoprotein cholesterol (HDL-C) particles and atherogenic Apo B-containing lipoproteins, primarily very low density lipoprotein (VLDL) and LDL particles [1]
The pre-specified efficacy hypotheses for LDL-C (BQ; primary) and HDL-C were both met in this study
The placebo-adjusted changes in LDL-C and HDL-C observed in this study were higher than the 29% reduction and 95% increase, respectively, seen for the same dose in a recently published, 24-week study conducted in non-Japanese patients with dyslipidemia [9]
Summary
The plasma protein cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl esters and triglycerides (TG) between high density lipoprotein cholesterol (HDL-C) particles and atherogenic Apo B-containing lipoproteins, primarily very low density lipoprotein (VLDL) and LDL particles [1]. Previous studies have shown favorable changes in lipids (i.e., lowered LDL-C and increased HDL-C) in patients with reduced CETP activity [2]. Pharmacologic inhibition of CETP may represent a potential therapeutic strategy for increasing HDL-C and lowering LDL-C in patients with dyslipidemia. The development of torcetrapib was halted prematurely due to an observed increase in major cardiovascular events and allcause mortality, possibly due to off-target activity on aldosterone synthesis and its sequelae [3]. We aimed to assess the effects of cholesteryl ester transfer protein inhibitor anacetrapib added to statin ± other lipid-modifying therapies (LMT) in Japanese patients with dyslipidemia who were not at their LDL-C goal. Conclusions: Long-term treatment with anacetrapib 100 mg substantially reduced LDL-C, increased HDLC and was well tolerated in Japanese patients with dyslipidemia (ClinicalTrials.gov number NCT01760460)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have